Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
QIMING U.S. VENTURES MANAGEMENT, LLC (CIK 1909617) reported $55.6M across 4 reported positions in its SEC 13F filing for 2025-09-30. Largest positions: TRML ($35.5M, 63.76%), KRRO ($17.6M, 31.68%), JSPR ($2.2M, 3.97%), KZR ($323,197, 0.58%), HLVX ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | TRML | TOURMALINE BIO INC | $35.5M | 63.76% | 741,691 | Hold |
| 2 | KRRO | KORRO BIO INC | $17.6M | 31.68% | 368,085 | Hold |
| 3 | JSPR | JASPER THERAPEUTICS INC | $2.2M | 3.97% | 928,964 | Hold |
| 4 | KZR | KEZAR LIFE SCIENCES INC | $323,197 | 0.58% | 82,871 | Hold |
| 5 | HLVX | HILLEVAX INC | $0 | 0.00% | 0 | Exited |
| 6 | VTYX | VENTYX BIOSCIENCES INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2025-09-30